Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Coeptis Therapeutics Holdings (COEP) has issued an announcement.
The Company’s Compensation Committee and Board of Directors have approved a significant incentive for CEO David Mehalick, awarding him options to acquire 2.4 million shares at the closing price on the date of approval, vested immediately with a 10-year term. Additionally, the firm announced the successful closure of their Series A Preferred sale in a recent press release.
See more data about COEP stock on TipRanks’ Stock Analysis page.